Who should not take HRT?

Whether HRT is appropriate for a given individual depends on many personal health factors that cannot be assessed through website content alone. According to current NAMS guidelines, certain conditions represent clear contraindications to systemic hormone therapy, while many others require individualized clinical evaluation rather than automatic avoidance.

Who should clearly avoid HRT

Active breast cancer: Per published clinical guidelines, systemic hormones are generally contraindicated during active breast cancer treatment, as estrogen may stimulate certain hormone-receptor-positive tumors. According to current NAMS guidelines, local vaginal estrogen is often considered separately because systemic absorption is minimal, and the decision requires oncology input.

Active or very recent blood clots: Per published clinical guidelines, a current deep vein thrombosis or pulmonary embolism is a contraindication to oral estrogen therapy. According to the Endocrine Society, transdermal estrogen (patch, gel, or spray) is associated with a substantially lower thrombotic risk compared with oral formulations, and may be considered in selected patients with specialist guidance once the acute event has resolved.

Unexplained vaginal bleeding: According to ACOG, any unexpected postmenopausal bleeding requires evaluation before initiating or continuing hormone therapy, as the underlying cause must be identified first.

Severe liver disease: Per published clinical guidelines, estrogen is hepatically metabolized, and advanced liver impairment may significantly affect its clearance. Transdermal routes bypass first-pass hepatic metabolism and may be evaluated by a specialist in carefully selected cases.

Situations where HRT may be used but needs careful discussion

• Past breast cancer in remission: According to current NAMS guidelines, systemic HRT is generally avoided in breast cancer survivors, though severe menopausal symptoms may be evaluated by an oncologist for individualized management options, including low-dose local vaginal estrogen.
• Migraine with aura: Per published clinical guidelines, oral estrogen may be associated with an elevated stroke risk in women with migraine with aura; transdermal estrogen at steady, low doses is typically preferred when hormone therapy is considered in this population.
• High cardiovascular risk: According to the WHI long-term follow-up data, women with uncontrolled hypertension or other cardiovascular risk factors require individualized risk assessment; transdermal estrogen is generally preferred over oral formulations when hormone therapy is considered.
• History of clotting disorders: Per the Endocrine Society, transdermal estrogen combined with an appropriate progestogen is preferred; oral estrogen is generally avoided in women with known thrombophilia.
• Gallbladder disease: Per published clinical guidelines, oral estrogen may increase biliary cholesterol saturation and worsen gallbladder symptoms; non-oral formulations are generally preferred in affected individuals.

Note on compounded hormone preparations

Some individuals are evaluated for compounded hormone formulations when commercially available doses or combinations do not meet their clinical needs. Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

Clinical guidance

According to current NAMS guidelines, absolute contraindications to HRT are relatively limited. For most women, whether hormone therapy is appropriate depends on the specific type, dose, and route of administration, alongside a complete review of individual health history. A prescriber should determine the most appropriate approach based on a patient's full medical history, current conditions, and personal risk profile.